Marinomed Biotech AG (DE:93Z)
FRANKFURT:93Z
Want to see DE:93Z full AI Analyst Report?
Eye Drops, Solution In Single-Dose Container
Allergic Conjunctivitis, Allergic Rhinitis
Phase II
Completed
Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis
Aug 21, 2020
―
Rhinocort, Budesolv
Allergic Conjunctivitis, Allergic Rhinitis, Hayfever
Phase III
Completed
Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray
Nov 21, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Marinomed Biotech AG (93Z) have in its pipeline
93Z is currently developing the following drugs: Eye Drops, Solution In Single-Dose Container, Rhinocort, Budesolv. These drug candidates are in various stages of clinical development as the company works toward FDA approval.